Travere Therapeutics Inc. Common Stock (TVTX)

FairStock Score: 33/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I begin with the business and the numbers, not the story. Travere sells therapies for rare kidney and metabolic diseases, and FILSPARI gives it a focused commercial franchise. The top line is moving: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $169.6M versus $114.4M in fiscal Q2 2025, and FY2025 revenue was $490.7M versus $233.2M in FY2024. That is real progress. But the bottom line remains the problem: fiscal Q2 2026 net loss was $34.8M, FY2025 net loss was $25.5M, FY2024 net loss was $321.5M, and the FairStock Lynch screen finds no category because the company lost money in each of the last four years. A moat in rare disease can come from regulatory exclusivity and specialist relationships, but those advantages have not yet produced durable owner earnings. Financial health is mixed: trailing free cash flow was $15.2M, but the FairStock FCF yield is only 0.3%, ROE is -236.36%, ROCE is -3.73%, Altman Z is 2.00, and Piotroski is 5/9. At the 2026-10-13 close of $51.80, FairStock's P/B is 48.41, EV/EBITDA is 931.45, and its FairStock Score is 33/100. That is not a Graham bargain; it is a growth option priced for success. I would need evidence that revenue growth converts into sustainable profits and cash before calling this cheap. The company has momentum, but the margin of safety is thin.

In plain English: Travere Therapeutics makes medicines for rare kidney and metabolic diseases, including FILSPARI. Sales are growing quickly, but the company has lost money in each of the last four years and still posted a net loss in the quarter ended 2026-06-30. At the 2026-10-13 close of $51.80, the price looks expensive compared with current profits and accounting value, so the market is betting heavily on future growth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer